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Summary
QUESTION UNDER STUDY: The epidemiology of pree-
clampsia in Switzerland is known only from a retrospective
registry study. This analysis aimed to prospectively determ-
ine the incidence of preeclampsia in a cohort of pregnant
women in Switzerland.
METHODS: Pregnant women presenting at gestational
week 11–14 at their obstetrician’s office were consecut-
ively included and prospectively followed-up until the end
of pregnancy. Ultrasound characteristics, blood pressure
measurements, body mass index, and personal history were
recorded. Duration of pregnancy, occurrence of preeclamp-
sia, birth weight and Apgar scores were recorded as out-
comes.
RESULTS: There were 1,300 pregnancies with follow-up
available for analysis. Median age was 30 years (interquart-
ile range [IQR] 27–33), median body mass index (BMI)
23.3 kg/m2 (IQR 21.2–26.1), median systolic blood pres-
sure 117 mm Hg (IQR 109–126) and median diastolic
blood pressure 70 mm Hg (IQR 64–77). A total of 30 wo-
men developed preeclampsia, corresponding to an inciden-
ce of 2.31% (95% confidence interval [CI] 1.62%–3.28%).
Of the women with preeclampsia, 6.66% (95% CI
2.04%–21.42%) had early-onset preeclampsia, 13.33%
(95% CI 5.45%–29.83%) progressed to eclampsia, whereas
10% (95% CI 3.63%–28.75%) developed HELLP syn-
drome (haemolysis, elevated liver enzymes, low platelet
count). Nulliparity and prior history of preeclampsia were
more frequently seen in pregnancies with preeclampsia
than in pregnancies without preeclampsia. BMI, as well as
systolic and diastolic blood pressure were higher in preg-
nancies subsequently developing preeclampsia.
CONCLUSION: The incidence of preeclampsia in
Switzerland is in line with frequencies observed elsewhere
in the world. Extrapolation to a national level indicates that
about 1,911 (range 1,340–2,713) preeclampsia cases per
year can be expected to occur in Switzerland.
Key words: eclampsia; HELLP syndrome; incidence;
outcomes; preeclampsia; pregnancy; risk factors; women
Introduction
Preeclampsia is a pregnancy complication unique to hu-
mans [1]. It is one of the hypertensive disorders of preg-
nancy characterised by endothelial dysfunction, high blood
pressure, and proteinuria arising in the second half of gest-
ation, but its exact definition and diagnostic criteria remain
a subject of debate [1–3].
The International Society for the Study of Hypertension
in Pregnancy (ISSHP) has proposed unified criteria for
diagnosing preeclampsia: correctly measured de novo hy-
pertension (systolic blood pressure ≥140 mm Hg and/or
diastolic blood pressure ≥90 mm Hg) after 20 weeks of
gestation that returns to normal postpartum, and proteinuria
of ≥300 mg/day, 1+ on dipstick or a protein/creatinine ratio
of ≥30 mg protein / mmol creatinine in a spot urine analysis
[4]. There are also other consensus definitions such as the
one proposed by the World Health Organization (WHO)
[5]. In order to predict or diagnose preeclampsia, several
serum and ultrasound markers are either under investiga-
tion or underway to being used in clinical routine [6–12].
According to severity, preeclampsia can be divided into
mild and severe forms. It can also be classified according
to the time of onset. Early-onset preeclampsia is defined
as developing, or leading to delivery, before 34 gestational
weeks, whereas late-onset preeclampsia occurs at week 34
or later [13, 14]. Earlier onset is associated with more
severe disease and worse outcomes for both mother and
child [14]. Sometimes a distinction is made between term
and preterm preeclampsia, the latter developing before 37
weeks of gestation [15].
Risks for developing preeclampsia include nulliparity, pri-
or preeclampsia, preexisting hypertension, renal disease,
gestational or preexisting diabetes mellitus, a family his-
tory of preeclampsia, maternal age of ≥35 years, multiple
gestation, obesity and a long interpregnancy interval [1,
16–18]. A change in paternity is a risk factor according to
some authors but not to others [1, 18, 19]. Smoking has
been shown to be a protective factor [18, 19]; however, if
the disease still develops, it is more severe and has poorer
outcomes than in nonsmokers [20]. There are inconsistent
data as to whether maternal age of <20 years is a predispos-
ing factor [1, 18, 21]. Black race is often found to be a risk
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factor [16]; the association of other races with heightened
risk of preeclampsia is not clear [22–24].
Preeclampsia is one of the leading causes of maternal and
perinatal morbidity and mortality, together with eclampsia
causing over 50,000 maternal deaths a year worldwide
[25]. Preeclampsia complicates around 2.2% of pregnan-
cies [26]. The incidence varies greatly between countries,
even inside Europe: figures based on the whole pregnant
population range from 2.2% in the Netherlands to 4.5% in
Norway, while in Finnish nulliparae aged 35 and over the
incidence of preeclampsia is as high as 9.4% [27–29]. So
far, there are no prospective data about the incidence of
preeclampsia in Switzerland. The aim of this study was to
assess the incidence of preeclampsia among Swiss women
and compare it with findings from other countries.
Methods
Study population
Study participants were recruited in the context of the
PRADO study (PRedictive mArkers for the Diagnosis Of
preeclampsia). The primary aim of this study was to identi-
fy biomarkers for recognition of women at high risk of de-
veloping preeclampsia. As a secondary aim, the PRADO
study provided the unique opportunity to describe the epi-
demiological characteristics of preeclampsia in Switzer-
land. Nine obstetricians based in private practices in the
French- and German-speaking regions of the Swiss Plateau
and the Jura Mountains consecutively recruited study par-
ticipants between July 2008 and January 2011. On the oc-
casion of an antenatal visit at the end of the first trimester,
pregnant women were invited to participate in the study.
Inclusion criteria were: gestational age between 6+0 and
13+6 weeks since the last menstrual period verified by use
of ultrasound; blood sample provided at gestational age
6+0 to 13+6 weeks; maternal age 18–45 years; singleton
pregnancy. Exclusion criteria were: multifetal pregnancy;
gestational age below 6+0 or above 13+6 weeks; maternal
age under 18 or over 45 years; mental retardation or other
mental disorders that raised doubts regarding the patient’s
willingness to participate in the study; lack of a blood
sample at the specified enrolment period. A flow chart il-
Figure 1
Flow chart of the study. The participating women were
subsequently recruited by nine obstetricians based in private
practices.
lustrating patient inclusion is given in figure 1. Written in-
formed consent was obtained from all patients who agreed
to participate in the study. The study was compliant with
the principles of the Declaration of Helsinki and approved
by the local institutional review board (Ethics Commission
of the Canton of Bern).
Data collection
On the occasion of the antenatal visit at the end of the
first trimester, each participant’s personal history and an-
thropometric measurements were collected, including in-
formation on parity, smoking status, blood pressure, body
mass index (BMI), age and ethnicity. Further, ultrasound
measurements were recorded, such as nuchal translucency
and crown-rump length. Gestational age since the last men-
strual period was determined from ultrasound measure-
ments. After birth or termination of pregnancy, the parti-
cipants were followed-up for occurrence of preeclampsia,
defined as blood pressure >140/90 mm Hg or a rise of >30
mm Hg in systolic and >20 mm Hg in diastolic, protein-
uria ≥300 mg / 24 h, with or without clinical symptoms
such as oedema, headaches and stomach aches, and brisk
reflexes. This follow-up information was recorded on a
questionnaire, which was systematically sent to the par-
ticipating obstetricians. If no response for follow-up was
obtained 11 months after the anticipated birth date (which
was calculated at the study centre for each study parti-
cipant) the obstetrician was contacted by telephone to ob-
tain the missing information. Early onset preeclampsia was
defined as preeclampsia with delivery before gestational
week 34. Eclampsia was defined as tonic-clonic seizures
unrelated to epilepsy and metabolic disorders. HELLP syn-
drome was defined as the occurrence of haemolysis, elev-
ated liver enzymes, and thrombocytopenia. Other charac-
teristics such as birth weight, placental weight, presence
of malformations, presence of intrauterine growth restric-
tion (IUGR; based on two measurements at least 2 weeks
apart providing evidence of the fetus not growing accord-
ing to the percentile curve), mode of birth, gestational age
at birth, and Apgar scores (1, 5 and 10 minutes after birth)
were also provided. IUGR was assessed according to indi-
vidual follow-up schemes for ultrasound measurements of
the participating obstetricians.
Statistical analysis
Statistical analysis was based on the included women and
not on completed pregnancies. Gestational weeks were ob-
tained from the calculated day of conception estimated by
use of ultrasound at inclusion. The data are presented as
medians and interquartile ranges (IQRs) or mean ± stand-
ard deviation, depending on the assessment with the
Kolmogorov-Smirnov test. Proportions are given with a
95% confidence interval (CI). Proportions were compared
by means of Fisher’s exact test, whereas tests for trends in
proportions are evaluated with the Cochran-Armitage test.
Medians were compared using the Mann-Whitney U-test,
whereas means are compared with Student’s t-test. Inciden-
ces are calculated for the date of enrolment into the study.
Birth weights according to presence or absence of pree-
clampsia were compared as percentiles adjusted for gesta-
tional age. For all comparisons, p-values <0.05 were con-
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sidered to be significant; p-values up to 0.20 were reported
numerically, whereas p-values >0.2 were reported as not
significant. All calculations are performed with MedCalc
software version 12.2.1 (MedCalc software, Mariakerke,
Belgium).
Results
The study population consisted of 1,511 women. Sixty wo-
men had two pregnancies during the study period; therefore
a total of 1,571 pregnancies were included in the study
cohort. The women presented at median gestational week
12+3 (IQR 12+0, 12+6). The baseline characteristics of the
study population are given in table 1. Follow-up data were
available for 1,300 pregnancies resulting in a follow-up
rate of 82.75%. It can be seen in table 1, that the women
with and without follow-up exhibit significant (but clin-
ically unimportant) differences only in BMI and the fre-
quency of Asian descent. Four women were excluded be-
cause of a twin gestation, seven women were under 18
years old upon enrolment and four women provided the
sample at a gestational age above 13+6 weeks. In order to
minimise the influence of missing follow-up data and ow-
ing to the fact that no meaningful differences between wo-
men with and without follow-up could be detected, the ana-
lysis was confined to women with follow-up.
The final analysis included 1,300 pregnancies, 30 of which
were preeclamptic. This reveals a preeclampsia incidence
of 2.31% (95% CI 1.62%–3.28%). Two of those women
had early-onset preeclampsia (0.15%; 0.05%–0.55%). Four
preeclampsia patients developed eclampsia, yielding a rate
of 0.31% (0.12%–0.79%), whereas three patients (0.23%;
0.08%–0.67%) progressed to HELLP syndrome. Fifteen
pregnancies did not result in the birth of a living baby, one
of which was from a woman with preeclampsia.
Women with preeclampsia had significantly earlier deliv-
ery than women without preeclampsia (median 37.50
weeks, IQR 36.75–38.21 vs 39.43 weeks, IQR
38.42‒40.29; p<0.001). Of the pregnancies affected by
preeclampsia, 6.67% (2.04%–21.42%; 2/30) showed an
early onset, with birth before gestational week 34. Thirty
percent (16.68%–48.04%; 9/30) of preeclamptic women
and 6.69% (5.45%–8.20%; 85/1,270) of healthy women
had a preterm birth (before 37 completed weeks of gest-
ation) (p <0.001); 0.23% (0.09%–0.69%; 3/1,270) of
healthy women and none of the preeclampsia patients had
a post-term birth (at least 42 gestational weeks).
The incidence of preeclampsia was highest in nulliparous
women (19/480; 3.96%, 95% CI 2.56%–6.10%) and de-
creased further from 1.60% (0.79%–3.27%; 7/437) in
second pregnancies to 0.92% (0.33%–2.65%; 3/327) in
third or later pregnancies. There was a significant decrease
of preeclampsia incidence with increasing parity (p for
trend = 0.003). Preeclampsia developed in 25.93%
(13.22%–44.87%; 7/27) of women with a prior history of
preeclampsia and in 0.41% (0.02%–1.20%; 3/726) of those
who had had previous pregnancies without preeclampsia (p
<0.001).
Women with preeclampsia were not significantly older than
women without preeclampsia, as seen in table 2. Women
up to 24 years old had an incidence of preeclampsia of
2.65% (1.17%–6.03%; 5/189). The incidence was 2.58%
(1.42%–4.68%; 10/388) in the age group 25–29, 2.30%
(1.30%–4.06%; 11/479) in women aged 30‒34 and 1.87%
(0.76%–4.69%; 4/214) in the group aged 35–39 years.
There were no preeclampsia cases at the age of 40 or more
(n = 27). There was neither a significant trend nor signific-
ant differences in preeclampsia incidence among these dif-
ferent age groups.
There was a significant difference in BMI between women
with and without preeclampsia (p = 0.047), as seen in
table 2. Women with normal weight (BMI 18.5–24.99
kg/m2) had a 1.99% (1.23%–3.21%; 16/804) incidence of
preeclampsia. Underweight women exhibited an incidence
of 2.44% (0.58%–12.57%; 1/41). The incidence of pree-
clampsia at higher BMI was 2.70% (1.39%–5.24%; 8/296)
in women with a BMI between 25 and 29.99 kg/m2 and
3.88% (1.71%–8.75%; 5/129) in women with a BMI of 30
or more. There was neither a significant trend nor signific-
ant differences in preeclampsia incidence among these dif-
ferent BMI groups.
Women with preeclampsia had significantly higher systolic
(p = 0.045) and diastolic (p = 0.015) blood pressure than
women without preeclampsia. At inclusion, systolic blood
pressure was >140 mm Hg in 47/1,270 (3.70%, 95% CI
2.80%–4.89%) pregnancies without preeclampsia and 3/30
(10%; 95% CI 3.63%–25.75%) (p = 0.09) in pregnancies
with preeclampsia, whereas diastolic blood pressure was
>90 mm Hg in 14/1,270 (1.10%; 95% CI% 0.66%–1.84%)
pregnancies without preeclampsia and in none of the wo-
men with preeclampsia. There were no statistically sig-
nificant differences in preeclampsia incidence between
smokers (1.47%; 2/136) and nonsmokers (2.41%; 27/
1,121). Nuchal translucency was similar in pregnancies
with and without preeclampsia (1.2 mm, IQR 1.0–1.5 vs
1.2 mm, IQR 1.0–1.4). There were 30 women with dia-
betes. None of them developed preeclampsia.
Neonates born to mothers with preeclampsia had signi-
ficantly lower birth weight (median 2,953 g, IQR
2,570–3,380) than neonates of mothers without preeclamp-
sia (median 3,300 g, IQR 3,010 –3,630) (p <0.001). Com-
paring the birth weight percentiles related to gestational
age in neonates of mothers with preeclampsia to those of
neonates born to mothers without preeclampsia revealed no
such statistical difference (p = 0.20). This suggests that the
difference in birth weight was mainly due to earlier deliv-
eries in cases of preeclampsia, although other reasons lead-
ing to lower birth weight, which were not investigated in
the present study, could also have contributed to this dif-
ference. Apgar scores of babies born to mothers with pree-
clampsia tended to be lower at 1 minute after birth (medi-
an 9, IQR 8–9; p = 0.08) but not after 5 (median 10, IQR
9‒10; p = 0.58) and 10 minutes (median 10, IQR 10‒10; p
= 0.58). The fetuses of three preeclampsia patients (10%;
3.63%‒25.75%) and 68 controls (5.35%; 4.25%‒6.73%)
suffered from intrauterine growth restriction. This differen-
ce was statistically not significant.
Discussion
This study suggests that the incidence of preeclampsia in
Switzerland is in line with the frequencies observed else-
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where in the world. When looking at European countries,
the incidence in Switzerland is at the lower end of the re-
ported frequencies. About 10% of all observed cases pro-
gressed to eclampsia, whereas another 10% progressed to
HELLP syndrome. About 7% of all preeclampsia cases
were early-onset preeclampsia. Nulliparity and prior his-
tory of preeclampsia were more frequently seen in preg-
nancies with preeclampsia than in pregnancies without
preeclampsia. BMI, as well as systolic and diastolic blood
pressure, were higher in pregnancies subsequently devel-
oping preeclampsia. As a result of a statistical type II error
arising from a relatively low number of preeclampsia cases,
some further associations between predisposing risk factors
and the occurrence of preeclampsia might have been
missed. Analogously, a type I error may also have occurred
in the analysis of the observed associations. Neonates of
women with preeclampsia were delivered earlier and ten-
ded to show lower 1-minute Apgar scores compared with
neonates born from uncomplicated pregnancies.
Our cohort had a mean maternal age of 31.0 years, a pro-
portion of 70.1% of vaginal deliveries, and a mean birth
weight of 3,282 g; 91.7% of study participants were of
Caucasian descent. This compares with national character-
istics of a mean maternal age at delivery of 30.8‒31.4 years
during the years of 2007‒2011 [30], a proportion of 69.9%
vaginal deliveries in 2004 [31], a mean birth weight of
3,296 g in 2011 [32], and a proportion of 91.8% of moth-
ers originating from Europe, North America or Oceania in
2011 [30]. These data suggest that our cohort can be con-
sidered to be representative of Switzerland.
There are many different definitions of preeclampsia. The
unified definition proposed by the ISSHP is mentioned
above in the introduction. In essence, it is blood pressure
≥140/90 in the second half of gestation that returns to nor-
mal postpartum, and proteinuria of ≥300 mg/day or 1+ on
a dipstick or a ratio of ≥30 mg of protein per mmol of cre-
atinine [4]. The WHO definition, on the other hand, con-
siders only diastolic blood pressure of ≥90 mmHg to be sig-
nificant [5]. Proteinuria is defined by the WHO as ≥300 mg
per litre, ≥300 mg in a 24-hour urine collection or ≥1+ on
dipstick, although it is recommended that the dipstick test
be verified by another test. In addition, the WHO definition
encompasses postpartum preeclampsia [5]. There are also
other definitions of preeclampsia. Our study employed the
following blood pressure and proteinuria criteria for pree-
clampsia: blood pressure >140/90 mm Hg or a rise of >30
Table 1: Maternal characteristics presented as median (interquartile range) or number of pregnancies (percentage) in women with and without follow-up. Characteristics
were obtained from pregnancies at gestational age 10+3 until 13+6 weeks.
Characteristic Follow-up
(n =1,300)
No follow-up
(n = 271)
p-value
Age at sampling (years) 30 (27–33) 30 (26–33) NS
<20 14 (1.1%) 2 (0.7%) NS
20–24 175 (13.5%) 35 (12.9%) NS
25–29 388 (29.8%) 89 (32.8%) NS
30–34 479 (36.8%) 96 (35.4%) NS
35–39 214 (16.5%) 44 (16.2%) NS
40–45 27 (2.1%) 5 (1.8%) NS
Unknown 3 (0.2%) 0 (0%) NS
Previous pregnancies (n) 1 (0–2) 1 (0–2) NS
0 480 (36.9%) 91 (33.6%) NS
1 437 (33.6%) 88 (32.5%) NS
2 213 (16.4%) 46 (17.0%) NS
3 69 (5.3%) 14 (5.2%) NS
4 30 (2.3%) 4 (1.5%) NS
5+ 15 (1.2%) 2 (0.7%) NS
Unknown 56 (4.3%) 26 (9.6%) 0.0009
Body mass index (kg/m2) 23.33 (21.18-26.07) 23.72 (21.77–26.89) 0.0339
<18.5 41 (3.2%) 5 (1.8%) NS
18.5–24.99 804 (61.8%) 162 (59.8%) NS
25–29.99 296 (22.8%) 64 (23.6%) NS
30–34.99 83 (6.4%) 25 (9.2%) 0.1120
35+ 46 (3.5%) 8 (3.0%) NS
Unknown 30 (2.3%) 7 (2.6%) NS
Smokers (%) 136 (10.5%) 28 (10.3%) NS
Diabetics (%) 30 (2.3%) 2 (0.7%) 0.1511
Ethnicity
Caucasian 1186 (91.2%) 241 (88.9%) NS
African 17 (1.3%) 5 (1.8%) NS
Asian 30 (2.3%) 13 (4.8%) 0.0374
Other 7 (0.5%) 0 (0%) NS
Unknown 60 (4.6%) 12 (4.4%) NS
SBP (mm Hg) 117 (109–126) 117 (108–125) NS
DBP (mm Hg) 70 (64–77) 71 (64–78) NS
Previous preeclampsia 16 (1.2%) 4 (1.5%) NS
DBP = diastolic blood pressure; NS = not statistically significant; SBP = systolic blood pressure
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mm Hg in systolic and >20 mm Hg in diastolic, proteinuria
≥300 mg/24 h. It is evident that unless a uniform defini-
tion of preeclampsia is available, incidences of preeclamp-
sia differ to some extent because of the different definitions
of preeclampsia employed.
There have been studies carried out to find the incidence
of preeclampsia in many countries. A secondary analysis
of the WHO Multicountry Survey on Maternal and New-
born Health (the survey itself was carried out between 2004
and 2008) contained data from 29 developing countries
[26]. Numbers range from 0.2% in Vietnam to 7.67% in
Nicaragua, with an incidence of 2.16% in total. Another
study measured the incidence of preeclampsia in eight re-
gions of developed countries [33]. There the range seems
to be smaller – from 1.4% in Alberta, Canada to 4.0% in
Norway. All the studies included in that paper were car-
ried out between 1997 and 2007. Other population-based
studies from Europe show a similar incidence range: from
2.2% in the Netherlands (2000–2008) to 4.5% in Norway
(1998–2002) [27, 28]. This present study shows that
Switzerland is at the lower end of the preeclampsia incid-
ence range in Europe. Nevertheless, with a total of 82,731
births registered in Switzerland during 2013 [30], the ob-
served preeclampsia incidence of 2.31% (95% CI
1.62%–3.28%) extrapolates to 1,911 preeclampsia cases
(range 1,340–2,713) occurring per year in Switzerland.
This is in accordance with 2,005 cases reported for the
year 2004 derived from a retrospective register-survey pub-
lished by the national office of statistics [31]. From a public
health perspective, these numbers will be important when it
comes to judging the cost-effectiveness of interventions al-
lowing for early recognition and treatment of women with
a high risk for development of preeclampsia.
The reported incidence range of early-onset preeclampsia
(defined as developing before or during the 34th gesta-
tional week) elsewhere in the world is 0.2%–1.4% [34,
35]. The incidence of HELLP syndrome is quoted as
0.17%–0.85% of all pregnancies [36], while three other
studies found it to be slightly lower than that [37–39]. In
the PRADO collective, HELLP syndrome with an incid-
ence of 0.19% (95% CI 0.07%–0.56%) and early-onset
preeclampsia with an incidence of 0.13% (95% CI
0.04%–0.46%) occur as frequently as in these other col-
lectives. Early-onset preeclampsia, however, is at the lower
range of frequencies observed elsewhere. Studies invest-
igating the incidence of preeclampsia in different regions
Table 2: Maternal characteristics presented as median (interquartile range) or number of pregnancies (percentage) in followed-up women with and without preeclampsia.
Characteristics were obtained from pregnancies at gestational age 10+3 until 13+6 weeks.
Characteristic Preeclampsia cases
(n = 30)
Normal pregnancies
(n = 1,270)
p-value
Age at sampling (years) 29.5 (26.25–34) 30 (27–33) NS
<20 1 (3.3%) 13 (1.0%) NS
20–24 4 (13.3%) 171 (13.5%) NS
25–29 10 (33.3%) 378 (29.8%) NS
30–34 11 (36.7%) 468 (36.9%) NS
35–39 4 (13.3%) 210 (16.5%) NS
40–45 0 (0%) 27 (2.1%) NS
Unknown 0 (0%) 3 (0.2%) NS
Previous pregnancies (n) 0 (0–1) 1 (0–2) 0.003
0 19 (63.3%) 461 (36.3%) 0.004
1 7 (23.3%) 430 (33.9%) NS
2 2 (6.7%) 211 (16.6%) NS
3 0 (0%) 69 (5.4%) NS
4 1 (3.3%) 29 (2.3%) NS
5+ 0 (0%) 15 (1.2%) NS
Unknown 1 (3.3%) 55 (4.3%) NS
Body mass index (kg/m2) 24.60 (22.11–28.27) 23.27 (21.16–26.04) 0.047
<18.5 1 (3.3%) 40 (3.1%) NS
18.5–24.99 16 (53.3%) 788 (62.0%) NS
25–29.99 8 (26.7%) 288 (22.7%) NS
30–34.99 3 (10.0%) 80 (6.3%) NS
35+ 2 (6.7%) 44 (3.5%) NS
Unknown 0 (0%) 30 (2.4%) NS
Smokers (%) 2 (6.7%) 134 (10.6%) NS
Diabetics (%) 0 (0%) 30 (2.4%) NS
Ethnicity
Caucasian 27 (90.0%) 1159 (91.3%) NS
African 1 (3.3%) 16 (1.3%) NS
Asian 1 (3.3%) 29 (2.3%) NS
other 0 (0%) 7 (0.6%) NS
Unknown 1 (3.3%) 59 (4.6%) NS
SBP (mm Hg) 123 (108–134) 117 (109–126) 0.045
DBP (mm Hg) 75 (68–81) 70 (64–77) 0.015
Previous preeclampsia 4 (13.3%) 12 (0.9%) 0.0003
DBP = diastolic blood pressure; NS = not statistically significant; SBP = systolic blood pressure
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of the world are summarised in figure 2. Further details
on the different reported incidences are given in table 3.
Variations in blood pressure, body weight, parity, age, and
glucose tolerance are associated with the incidence of pree-
clampsia. Further, the incidence of preeclampsia is also de-
pendent on the quality of antenatal care [33]. Although the
present study was not designed to identify factors leading
to a low incidence of preeclampsia, it can be hypothesised
that the distribution and composition of risk factors leading
to preeclampsia is supposedly favourable in Switzerland,
when compared with other countries.
Commonly quoted risk factors for developing preeclampsia
are nulliparity, advanced maternal age, obesity, multiple
gestation, prior preeclampsia and preexisting diseases like
diabetes and chronic hypertension [1, 16–18]. Further, par-
ity >3 represents another risk factor for preeclampsia,
which, owing to the low median number of children per
woman, is often ignored in the Western world [40]. As a
result of the relatively rare occurrence of preeclampsia in
our study, not all associations could be confirmed owing
to statistical type II error. However, we found the occur-
rence of preeclampsia to be significantly correlated with
prior preeclampsia, high BMI, and both systolic and dia-
stolic blood pressure.
Adverse effects of preeclampsia for the mother include pul-
monary oedema, cerebral haemorrhage, disseminated in-
travascular coagulation and renal failure [5, 41]. A history
of preeclampsia is associated with a higher risk of renal
and cardiovascular diseases later in life [42]. The baby is at
risk of intrauterine growth restriction, premature birth, low
birth weight, hypertension, cardiovascular disease, and dia-
Figure 2
Observed incidence of preeclampsia in the Swiss PRADO study
compared with worldwide and regional incidences.
X denotes a point incidence observed at a specific period of time in
a specific country. A bold horizontal line indicates the median of all
observed incidences within a regional group. Data are taken from
references [18, 26, 27, 33, 43–57] and are specified in more detail
in table 3. Summary data from WHOMCS (World Health
Organization Multicountry Survey on Maternal and Newborn
Health) originate from reference [26].
betes later in life [1, 5, 16, 19, 41]. We could reproduce the
correlation of preeclampsia with preterm delivery.
The main limitation of this study was its relatively small
sample of preeclampsia cases. As the occurrence of pree-
clampsia is a rare event, a small sample size hinders the
detection of all risk factors and outcomes. However, some
strongly correlated factors were found, and the main focus
of the study was to determine the incidence of preeclamp-
sia, not the risk factors for its development. In addition, we
proposed a standard definition for diagnosing preeclamp-
sia but did not get a detailed report on how it actually
was diagnosed (i.e., exact specification of blood pressure
and proteinuria at diagnosis). Thirdly, follow-up data were
available for about 83% of the cases, which might intro-
duce bias. However, when comparing the women with and
without follow-up, it can be seen that the two groups do not
differ in a meaningful manner. Two of nearly 40 statistical
tests in this comparison were significant, leading to an in-
herent statistical type I error. In our view the comparability
of the women with and without follow-up validates our ap-
proach of restricting the analysis to women with follow-up.
Lastly, since multiple gestation was an exclusion criterion,
our results may not be valid for women benefitting from ar-
tificial reproductive technologies (ART). We consider the
potential for bias small as only about 2% of deliveries in
Switzerland occur following ART. In sum, we do not be-
lieve that these limitations invalidate our findings.
To our knowledge, the present study is the first to describe
the incidence of preeclampsia in Switzerland by means of
a prospective study. Our reported incidence, 2.31%, is in
line with the mean incidence reported worldwide. Among
European countries, the preeclampsia incidence observed
in our study is at the lower end of observed frequencies.
Nevertheless, extrapolation to a national level indicates that
a sizeable number of 1,340–2,713 preeclampsia cases per
year are currently occurring in Switzerland.
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Figures (large format)
Figure 1
Flow chart of the study. The participating women were subsequently recruited by nine obstetricians based in private practices.
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Figure 2
Observed incidence of preeclampsia in the Swiss PRADO study compared with worldwide and regional incidences.
X denotes a point incidence observed at a specific period of time in a specific country. A bold horizontal line indicates the median of all observed
incidences within a regional group. Data are taken from references [18, 26, 27, 33, 43–57] and are specified in more detail in table 3. Summary
data from WHOMCS (World Health Organization Multicountry Survey on Maternal and Newborn Health) originate from reference [26].
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